Compare ONEG & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONEG | MRKR |
|---|---|---|
| Founded | 2021 | 1999 |
| Country | Hong Kong | United States |
| Employees | 26 | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3M | 27.7M |
| IPO Year | N/A | 2010 |
| Metric | ONEG | MRKR |
|---|---|---|
| Price | $10.83 | $1.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.5M | 132.2K |
| Earning Date | 01-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $936.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.96 | $0.81 |
| 52 Week High | $13.50 | $4.07 |
| Indicator | ONEG | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 95.74 | 51.74 |
| Support Level | $10.26 | $1.34 |
| Resistance Level | $12.04 | $1.55 |
| Average True Range (ATR) | 1.13 | 0.09 |
| MACD | 0.50 | -0.01 |
| Stochastic Oscillator | 62.71 | 44.91 |
OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. The company is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction project includes performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: MT-601; and MT-401-OTS.